BNP Chairperson Khaleda Zia has recovered from fever and body pain that she experienced as side effects after taking the first dose of the Moderna Covid-19 vaccine. “Madam (Khaleda) was affected with light fever and body pain as the side effects of the first dose of the Covid vaccine. But her fever and pain have already subsided,” the BNP chief’s personal physician, Dr Al Mamun, told UNB on Friday. He, however, said Khaleda is still suffering from heart, lung, and some other complications. The 76-year-old BNP chief, who recovered from Covid-19 over two months back, has now been receiving medical treatment at her Gulshan house for those complications. Read: Khaleda takes 1st dose of Covid vaccine On Monday, Khaleda received the first dose of the Moderna Covid-19 vaccine at Sheikh Russel Gastro Liver Institute and Hospital in the city’s Mohakhali area. She is scheduled to get the second dose of the vaccine on August 19. On April 11, she tested positive for Covid-19 and she was admitted to Evercare Hospital on April 27. The BNP chief tested negative for Covid-19 on May 8, 27 days after she had been infected with the deadly virus. Read: Khaleda receives vaccination SMS: Dr Zahid On June 19, Khaleda Zia got back home from the hospital after 53 days of treatment for Covid infections and other physical complications. Amid the coronavirus outbreak, the government temporarily freed Khaleda Zia from jail through an executive order suspending her sentences on March 25 last year.

British authorities recommended Wednesday that the AstraZeneca COVID-19 vaccine not be given to adults under 30 where possible because of strengthening evidence that the shot may be linked to rare blood clots.   The recommendation came as regulators in the United Kingdom and the European Union emphasized that the benefits of receiving the vaccine continue to outweigh the risks for most people — even though the European Medicines Agency said it had found a “possible link” between the shot and the rare clots. British authorities recommended that people under 30 be offered alternatives to AstraZeneca. But the EMA advised no such age restrictions, leaving it up to its member-countries to decide whether to limit its use.   Also Read: EU agency: Rare clots possibly linked to AstraZeneca shot   Several countries have already imposed limits on who can receive the vaccine, and any restrictions are closely watched since the vaccine, which is cheaper and easier to store than many others, is critical to global immunization campaigns and is a pillar of the U.N.-backed program known as COVAX that aims to get vaccines to some of the world’s poorest countries.   “This is a course correction, there’s no question about that,” Jonathan Van-Tam, England’s deputy chief medical officer, said during a news briefing.   Van-Tam said the effect on Britain’s vaccination timetable — one of the speediest in the world — should be “zero or negligible,” assuming the National Health Service receives expected deliveries of other vaccines, including those produced by Pfizer-BioNTech and Moderna. EU and U.K. regulators held simultaneous news conferences Wednesday to announce the results of investigations into reports of blood clots that sparked concern about the rollout of the AstraZeneca vaccine.   The EU agency described the clots as “very rare” side effects. Dr Sabine Straus, chair of its Safety Committee, said the best data was from Germany, where there was one report of the clots for every 100,000 doses given, although she noted far fewer reports in the U.K. Still, that’s less than the clot risk that healthy women face from birth control pills, noted another expert, Dr. Peter Arlett.   The agency said most of the cases reported were in women under 60 within two weeks of vaccination, though it was unable to identify specific risk factors based on current information. Experts reviewed several dozen cases that came mainly from Europe and the U.K., where around 25 million people have received the AstraZeneca vaccine.   “The risk of mortality from COVID is much greater than the risk of mortality from these side effects,” said Emer Cooke, the EMA’s executive director.   Arlett said there is no information suggesting an increased risk from the other major COVID-19 vaccines.   In a statement, AstraZeneca said both UK and EU regulators had requested their vaccine labels be updated to warn of these “extremely rare potential side effect(s).”   “Both of these reviews reaffirmed the vaccine offers a high-level of protection against all severities of COVID-19 and that these benefits continue to far outweigh the risks,” it said.   The EMA’s investigation focused on unusual types of blood clots that have occurred along with low blood platelets. One rare clot type appears in multiple blood vessels and the other in veins that drain blood from the brain.   “We are not advising a stop to any vaccination for any individual in any age group,” said Wei Shen Lim, who chairs Britain’s Joint Committee on Vaccination and Immunization. “We are advising a preference for one vaccine over another vaccine for a particular age group ... out of the utmost caution rather than because we have any serious safety concerns.”   In March, more than a dozen countries, mostly in Europe, suspended their use of AstraZeneca over the blood clot issue. Most restarted — some with age restrictions — after the EMA said countries should continue using the vaccine.   Britain, which relies heavily on AstraZeneca, however, continued to use it.   The suspensions were seen as particularly damaging for AstraZeneca because they came after repeated missteps in how the company reported data on the vaccine’s effectiveness and concerns over how well its shot worked in older people. That has led to frequently changing advice in some countries on who can take the vaccine, raising worries that AstraZeneca’s credibility could be permanently damaged, spurring more vaccine hesitancy and prolonging the pandemic. Dr. Peter English, who formerly chaired the British Medical Association’s Public Health Medicine Committee, said the back-and-forth over the AstraZeneca vaccine could have serious consequences. “We can’t afford not to use this vaccine if we are going to end the pandemic,” he said. In some countries, authorities have already noted hesitancy toward the AstraZeneca shot.   “People come and they are reluctant to take the AstraZeneca vaccine, they ask us if we also use anything else,” said Florentina Nastase, a doctor and coordinator at a vaccination center in Bucharest, Romania. “There were cases in which people didn’t show up, there were cases when people came to the center and saw that we use only AstraZeneca and refused (to be inoculated).”   After the EMA announcement Wednesday, officials in Spain said AstraZeneca would be limited to people over 60 years of age, and Italy issued a similar recommendation.   Belgium’s health minister, Frank Vandenbroucke, declared a four-week ban on administering the AstraZeneca vaccine to people under 56, but said that would have little impact on the vaccination campaign, since few from that age group are in line to get the shots this month.   Earlier Wednesday, South Korea had said it would temporarily suspend the use of AstraZeneca’s vaccine in people 60 and younger. In that age group, the country is only currently vaccinating health workers and people in long-term care settings.   “For the vast majority of people the benefits of the Oxford AZ vaccine far outweigh any extremely small risk,″ said Dr. Anthony Harnden, the deputy chair of Britain’s vaccination committee. “And the Oxford AZ vaccine will continue to save many from suffering the devastating effects that can result from a COVID infection.”  

Authorities in Berlin and Munich are again suspending the use of AstraZeneca’s coronavirus vaccine for residents under age 60 due to new reports of unusual blood clots in people who recently received the shots, officials said Tuesday. The action was taken as a precaution ahead of a meeting later Tuesday of representatives from Germany’s 16 states and further recommendations expected from national medical regulators, said Berlin’s top health official, Dilek Kalayci. Also Read: Sweden is latest country to stop using AstraZeneca vaccine The decision came after the country’s medical regulator announced that it had received a total of 31 reports of rare blood clots in recent recipients of the AstraZeneca vaccine. Nine of the people died and all but two of the cases involved women aged 20 to 63, the Paul Ehrlich Institute said. Also Read: Major European nations suspend use of AstraZeneca vaccine Reports of an unusual form of blood clot in the head, known as sinus vein thrombosis, prompted several European countries to temporarily halt the use of the AstraZeneca vaccine earlier this month. After a review by medical experts, the European Medicines Agency concluded the benefits of the vaccine outweighed the risks. Also Read: Canada pauses AstraZeneca vaccine for under 55 At the same time, the agency recommended that warnings about possible rare side effects should be provided to patients and doctors. Most European Union countries, including Germany, resumed use of the vaccine. Earlier Tuesday, two state-owned hospitals in Berlin announced that they had stopped giving the AstraZeneca vaccine to female staff members under 55. The heads of five university hospitals in western Germany called for a temporary halt to the vaccine for all younger women, citing the blood clot risk. Kalayci, the Berlin state health minister, said the suspension of AstraZeneca vaccines for younger people was done as a precaution. “We have not had a case of serious side effects in Berlin yet,” she said, adding that all of those who had received the AstraZeneca shot already could rest assured that it provides good protection against the coronavirus. “Still, we need to treat it carefully and wait for the talks taking place at the federal level,” said Kalayci. The decision could affect appointments for tens of thousands of teachers and people with preexisting conditions who received invitations to get vaccinated in Germany’s capital in recent days. German news agency dpa quoted a spokesman for Munich, the country’s third-largest city, saying that the suspension of AstraZeneca vaccinations for people younger than 60 would last “until issue of possible vaccine complications for this group of persons has been resolved.” Some 2.7 million doses of the AstraZeneca vaccine have been administered across the whole of Germany so far. Some other European countries remain hesitant about giving the AstraZeneca shot to older people. In Madrid, residents ages 60 to 65 started receiving the vaccine Tuesday ahead of those between the ages of 66 and 79 because Spanish authorities have not yet reviewed new data provided by AstraZeneca about how well it works in the older age group. Spain is currently using the Pfizer/BioNTech and Moderna vaccines for people over 80 years old. Spanish health authorities have said that they are hoping to speed up the rollout of vaccines with the arrival of the jab developed by the pharmaceutical company Janssen, a subsidiary of Johnson & Johnson, which has also been approved for use in Europe and requires one shot only. Authorities in Berlin and Munich are again suspending the use of AstraZeneca’s coronavirus vaccine for residents under age 60 due to new reports of unusual blood clots in people who recently received the shots, officials said Tuesday. The action was taken as a precaution ahead of a meeting later Tuesday of representatives from Germany’s 16 states and further recommendations expected from national medical regulators, said Berlin’s top health official, Dilek Kalayci. The decision came after the country’s medical regulator announced that it had received a total of 31 reports of rare blood clots in recent recipients of the AstraZeneca vaccine. Nine of the people died and all but two of the cases involved women aged 20 to 63, the Paul Ehrlich Institute said. Reports of an unusual form of blood clot in the head, known as sinus vein thrombosis, prompted several European countries to temporarily halt the use of the AstraZeneca vaccine earlier this month. After a review by medical experts, the European Medicines Agency concluded the benefits of the vaccine outweighed the risks. At the same time, the agency recommended that warnings about possible rare side effects should be provided to patients and doctors. Most European Union countries, including Germany, resumed use of the vaccine. Earlier Tuesday, two state-owned hospitals in Berlin announced that they had stopped giving the AstraZeneca vaccine to female staff members under 55. The heads of five university hospitals in western Germany called for a temporary halt to the vaccine for all younger women, citing the blood clot risk. Kalayci, the Berlin state health minister, said the suspension of AstraZeneca vaccines for younger people was done as a precaution. “We have not had a case of serious side effects in Berlin yet,” she said, adding that all of those who had received the AstraZeneca shot already could rest assured that it provides good protection against the coronavirus. “Still, we need to treat it carefully and wait for the talks taking place at the federal level,” said Kalayci. The decision could affect appointments for tens of thousands of teachers and people with preexisting conditions who received invitations to get vaccinated in Germany’s capital in recent days. German news agency dpa quoted a spokesman for Munich, the country’s third-largest city, saying that the suspension of AstraZeneca vaccinations for people younger than 60 would last “until issue of possible vaccine complications for this group of persons has been resolved.” Some 2.7 million doses of the AstraZeneca vaccine have been administered across the whole of Germany so far. Some other European countries remain hesitant about giving the AstraZeneca shot to older people. In Madrid, residents ages 60 to 65 started receiving the vaccine Tuesday ahead of those between the ages of 66 and 79 because Spanish authorities have not yet reviewed new data provided by AstraZeneca about how well it works in the older age group. Spain is currently using the Pfizer/BioNTech and Moderna vaccines for people over 80 years old. Spanish health authorities have said that they are hoping to speed up the rollout of vaccines with the arrival of the jab developed by the pharmaceutical company Janssen, a subsidiary of Johnson & Johnson, which has also been approved for use in Europe and requires one shot only.